170 related articles for article (PubMed ID: 21235517)
1. LYP3, a new bestatin derivative for aminopeptidase N inhibition.
Luan Y; Ma C; Sui Z; Wang X; Feng J; Liu N; Jing F; Wang Y; Li M; Fang H; Xu W
Med Chem; 2011 Jan; 7(1):32-6. PubMed ID: 21235517
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and activity evaluation of a new bestatin derivative LYP2 as an aminopeptidase N inhibitor.
Luan Y; Wang Q; Liu N; Mou J; Jiao X; Fang H; Li M; Xu W
Anticancer Drugs; 2011 Jan; 22(1):99-103. PubMed ID: 21048494
[TBL] [Abstract][Full Text] [Related]
3. LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin.
Gao JJ; Gao ZH; Zhao CR; Yuan Y; Cui SX; Zhang XF; Cheng YN; Xu WF; Tang W; Qu XJ
Invest New Drugs; 2011 Aug; 29(4):574-82. PubMed ID: 20111888
[TBL] [Abstract][Full Text] [Related]
4. Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
Cao J; Zang J; Kong X; Zhao C; Chen T; Ran Y; Dong H; Xu W; Zhang Y
Bioorg Med Chem; 2019 Mar; 27(6):978-990. PubMed ID: 30737134
[TBL] [Abstract][Full Text] [Related]
5. The effect of different species aminopeptidase N structure on the activity screening of aminopeptidase N inhibitor.
Wang X; Zhang L; Yang K; Zhang C; Zhang J; Fang H; Xu W
Biol Pharm Bull; 2010; 33(10):1658-65. PubMed ID: 20930372
[TBL] [Abstract][Full Text] [Related]
6. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin.
Shim JS; Kim JH; Cho HY; Yum YN; Kim SH; Park HJ; Shim BS; Choi SH; Kwon HJ
Chem Biol; 2003 Aug; 10(8):695-704. PubMed ID: 12954328
[TBL] [Abstract][Full Text] [Related]
7. Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
Cao J; Ma C; Zang J; Gao S; Gao Q; Kong X; Yan Y; Liang X; Ding Q; Zhao C; Wang B; Xu W; Zhang Y
Bioorg Med Chem; 2018 Jul; 26(12):3145-3157. PubMed ID: 29859750
[TBL] [Abstract][Full Text] [Related]
8. Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells.
Mishima Y; Matsumoto-Mishima Y; Terui Y; Katsuyama M; Yamada M; Mori M; Ishizaka Y; Ikeda K; Watanabe J; Mizunuma N; Hayasawa H; Hatake K
J Natl Cancer Inst; 2002 Jul; 94(13):1020-8. PubMed ID: 12096087
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of bestatin in the retina of streptozotocin-induced diabetic mice.
Hossain A; Heron D; Davenport I; Huckaba T; Graves R; Mandal T; Muniruzzaman S; Wang S; Bhattacharjee PS
Exp Eye Res; 2016 Aug; 149():100-106. PubMed ID: 27344955
[TBL] [Abstract][Full Text] [Related]
10. Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC.
Cao J; Zhao W; Zhao C; Liu Q; Li S; Zhang G; Chou CJ; Zhang Y
Molecules; 2020 Oct; 25(21):. PubMed ID: 33126591
[TBL] [Abstract][Full Text] [Related]
11. Effect of ubenimex (Bestatin) on the cell growth and phenotype of HL-60 and HL-60R cell lines: up-and down-regulation of CD13/aminopeptidase N.
Imamura N; Kimura A
Leuk Lymphoma; 2000 May; 37(5-6):663-7. PubMed ID: 11042531
[TBL] [Abstract][Full Text] [Related]
12. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and preliminary activity evaluation of novel L-lysine derivatives as aminopeptidase N/CD13 inhibitors.
Wang Q; Xu F; Mou J; Zhang J; Shang L; Luan Y; Yuan Y; Liu Y; Li M; Fang H; Wang B; Xu W
Protein Pept Lett; 2010 Jul; 17(7):847-53. PubMed ID: 20156182
[TBL] [Abstract][Full Text] [Related]
14. Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer.
Tsukamoto H; Shibata K; Kajiyama H; Terauchi M; Nawa A; Kikkawa F
BMC Cancer; 2008 Mar; 8():74. PubMed ID: 18366676
[TBL] [Abstract][Full Text] [Related]
15. Design of Aminopeptidase N Inhibitors as Anti-cancer Agents.
Amin SA; Adhikari N; Jha T
J Med Chem; 2018 Aug; 61(15):6468-6490. PubMed ID: 29630364
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of human endometrial stromal decidualization by bestatin, an aminopeptidase-N inhibitor.
Tanaka T; Umesaki N; Masuda M; Mizuno K; Ogita S
Gynecol Endocrinol; 2000 Jun; 14(3):182-6. PubMed ID: 10923279
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel chloramphenicol amine derivatives as potent aminopeptidase N (APN/CD13) inhibitors.
Yang K; Wang Q; Su L; Fang H; Wang X; Gong J; Wang B; Xu W
Bioorg Med Chem; 2009 Jun; 17(11):3810-7. PubMed ID: 19423354
[TBL] [Abstract][Full Text] [Related]
18. Laeverin/aminopeptidase Q, a novel bestatin-sensitive leucine aminopeptidase belonging to the M1 family of aminopeptidases.
Maruyama M; Hattori A; Goto Y; Ueda M; Maeda M; Fujiwara H; Tsujimoto M
J Biol Chem; 2007 Jul; 282(28):20088-96. PubMed ID: 17525158
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.
Mou J; Fang H; Jing F; Wang Q; Liu Y; Zhu H; Shang L; Wang X; Xu W
Bioorg Med Chem; 2009 Jul; 17(13):4666-73. PubMed ID: 19454370
[TBL] [Abstract][Full Text] [Related]
20. Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo.
Yamashita M; Kajiyama H; Terauchi M; Shibata K; Ino K; Nawa A; Mizutani S; Kikkawa F
Int J Cancer; 2007 May; 120(10):2243-50. PubMed ID: 17266036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
